Pixium Vision (PA:PIX) is building up a sales channel across Europe for its Iris II device, and is working on securing reimbursement and generating initial product sales in H217. It is also planning to start first-in-human trials for the next-generation Prima implant in H217. Using a risk-adjusted NPV model, we obtain a pipeline rNPV of €129.3m, compared to €131.4m, previously.
Interim Iris II data can support French reimbursement
Pixium plans to provide interim six-month data from its 10-patient European Iris II study in Q317, which it believes will support its application for provisional Iris II reimbursement in France under the Forfait Innovation (FI) programme. A positive decision could potentially support up to 40 funded implantations at French hospitals and the associated rehabilitation training.
To read the entire report Please click on the pdf File Below: